A development-stage biotechnology company based in Sarasota, Florida, Oragenics focuses on nasal delivery formulations for pharmaceutical applications in neurology and infectious disease treatment. The company's primary development effort centers on ONP-002, a synthetic neurosteroid designed to treat mild traumatic brain injury. The drug candidate crosses the blood-brain barrier to address swelling, oxidative stress, and inflammation while supporting cerebral blood flow restoration.
The company's pipeline also includes NT-CoV-2-1, a SARS-CoV-2 vaccine candidate, and lantibiotics—compounds with potential antimicrobial properties. These programs represent the company's dual strategic focus on neurological conditions and infectious disease prevention.
Oragenics operates with a minimal workforce of three full-time employees and maintains operations in the United States. The company was incorporated in Florida in 1996 under its former name, Oragen, Inc. As a development-stage enterprise, the company has not yet commercialized products and remains dependent on capital financing to support ongoing research and development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.60 | $-1.60 | +82.6% | |
| 2023 | $-9.18 | $-9.18 | -29.1% | |
| 2022 | — | $-7.11 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-14 | 0001493152-25-010389 | SEC ↗ |
| 2023-12-31 | 2024-03-29 | 0001493152-24-011979 | SEC ↗ |
| 2022-12-31 | 2023-04-17 | 0001493152-23-012617 | SEC ↗ |
| 2021-12-31 | 2022-03-24 | 0001493152-22-007664 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001493152-21-005122 | SEC ↗ |
| 2019-12-31 | 2020-03-04 | 0001493152-20-003343 | SEC ↗ |
| 2018-12-31 | 2019-03-29 | 0001564590-19-010173 | SEC ↗ |
| 2017-12-31 | 2018-02-16 | 0001193125-18-048564 | SEC ↗ |
| 2016-12-31 | 2017-02-27 | 0001193125-17-058912 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001193125-16-523810 | SEC ↗ |
| 2014-12-31 | 2015-02-27 | 0001193125-15-070177 | SEC ↗ |
| 2013-12-31 | 2014-02-28 | 0001193125-14-077374 | SEC ↗ |
| 2012-12-31 | 2013-03-26 | 0001193125-13-126950 | SEC ↗ |
| 2011-12-31 | 2012-04-16 | 0001193125-12-163736 | SEC ↗ |
| 2010-12-31 | 2011-03-30 | 0001193125-11-082222 | SEC ↗ |
| 2009-12-31 | 2010-03-31 | 0001144204-10-016984 | SEC ↗ |
| 2008-12-31 | 2009-04-01 | 0001144204-09-018117 | SEC ↗ |